TherapeuticsMD, an Innovative Women’s Healthcare Company, & PlushCare, a Virtual Health Platform, Announce Enhanced Access ...
January 07 2020 - 6:30AM
Business Wire
Arrangement advances access to quality
healthcare for women
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s
healthcare company, and PlushCare, a virtual health platform that
enables patients to book a virtual doctor’s appointment to get
treatment, today announced that TherapeuticsMD’s women’s health
products can be prescribed to patients via the PlushCare
platform.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200107005077/en/
“We are excited that women have an option to receive care via
the PlushCare virtual care platform, which provides a convenient
alternative for women to connect and talk to a doctor about
menopausal and reproductive treatment options,” said TherapeuticsMD
Chief Commercial Officer Dawn Halkuff.
“Oftentimes women’s health problems can be easily dismissed or
overlooked, and now with companies like TherapeuticsMD, women’s
health is being taken more seriously. We are extremely proud and
excited to offer access to products like TherapeuticsMD’s as we are
continuously working to meet the demands of our patients,” said
PlushCare co-founder and CEO, Ryan McQuaid.
PlushCare is a virtual health platform offering affordable
primary care medical services to patients in all 50 U.S. states.
Having treated over 100,000 patients and diagnosed over 3,500
medical conditions, PlushCare is changing the medical landscape and
offering affordable and accessible healthcare to all.
For more information on PlushCare or TherapeuticsMD, please
visit Plushcare.com or TherapeuticsMD.com.
About PlushCare:
PlushCare is a virtual health platform that offers primary
healthcare and virtual doctor’s visits to patients in all 50 U.S.
states. With over 100,000 users and counting, patients are
connected to physicians from the top 50 medical institutions in the
country via desktop or mobile devices. PlushCare accepts most major
insurance plans, and patients have access to quality primary care
consultations and can get diagnosed, treated, prescribed medication
or have lab testing. The PlushCare platform for virtual health
provides a unique combination of doctors, on-demand lab testing,
affordable pricing, and same-day appointments with the patient's
choice of provider. Treating over 3,500 medical conditions,
PlushCare strives to make patient’s healthcare experience with
doctors stress-free and is available on the PlushCare mobile app
for iOS and Android or via PlushCare.com.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare
company, focused on developing and commercializing novel products
exclusively for women. Our products are designed to address the
unique changes and challenges women experience through the various
stages of their lives with a therapeutic focus in family planning,
reproductive health, and menopause management. The company is
committed to advancing the health of women and championing
awareness of their healthcare issues. To learn more about
TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on
Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include,
but are not limited to, statements relating to TherapeuticsMD’s
objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments
that the company intends, expects, projects, believes or
anticipates will or may occur in the future. These statements are
often characterized by terminology such as “believes,” “hopes,”
“may,” “anticipates,” “should,” “intends,” “plans,” “will,”
“expects,” “estimates,” “projects,” “positioned,” “strategy” and
similar expressions and are based on assumptions and assessments
made in light of management’s experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company’s control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled “Risk Factors” in
the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K
and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K,
and include the following: the company’s ability to maintain or
increase sales of its products; the company’s ability to develop
and commercialize IMVEXXY®, ANNOVERA™, BIJUVA® and its hormone
therapy drug candidates and obtain additional financing necessary
therefor; whether the company will be able to comply with the
covenants and conditions under its term loan facility, including
the conditions to draw additional tranches thereunder; the
potential of adverse side effects or other safety risks that could
adversely affect the commercialization of the company’s current or
future approved products or preclude the approval of the company’s
future drug candidates; the length, cost and uncertain results of
future clinical trials; the company’s reliance on third parties to
conduct its manufacturing, research and development and clinical
trials; the ability of the company’s licensees to commercialize and
distribute the company’s products; the availability of
reimbursement from government authorities and health insurance
companies for the company’s products; the impact of product
liability lawsuits; the influence of extensive and costly
government regulation; the volatility of the trading price of the
company’s common stock and the concentration of power in its stock
ownership. PDF copies of the company’s historical press releases
and financial tables can be viewed and downloaded at its
website: www.therapeuticsmd.com/pressreleases.aspx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200107005077/en/
TherapeuticsMD Investor
ContactNichol OchsnerVice President, Investor
Relations561-961-1900, ext. 2088Nochsner@TherapeuticsMD.com
PlushCare Media ContactNandi
Millett5W Public Relationsnmillett@5wpr.com646-763-8297
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Apr 2023 to Apr 2024